Increased intrathecal production of apolipoprotein D in multiple sclerosis

Area of Science:

• Neuroscience
• Biochemistry
• Immunology

Background:

• Apolipoprotein D (apoD) is a glycoprotein involved in lipid transport.
• Within the nervous system, apoD may act as an acute phase protein, aiding lipid metabolism during nerve degeneration and regeneration.
• Its role in various neuropathologies is under investigation.

Purpose of the Study:

• To measure cerebrospinal fluid (CSF) and serum apoD levels in patients with multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), infectious inflammatory neurological diseases (IND), and non-inflammatory neurological diseases (NND).
• To investigate the diagnostic and prognostic significance of apoD in these neurological conditions, particularly MS.

Main Methods:

• Measurement of apoD levels in CSF and serum from patients with various neurological diseases.
• Calculation of the apoD index to assess intrathecal apoD production.
• Correlation analysis of apoD levels and indices with clinical parameters such as disease duration, disability, age, and exacerbation status.

Main Results:

• Significantly increased CSF apoD levels were observed in CIDP/GBS patients, indicating acute blood-nerve barrier leakage.
• MS patients demonstrated an increased intrathecal apoD release, evidenced by a higher apoD index.
• The apoD index was highest in MS patients during their first clinical exacerbation and correlated with disease duration, but not disability or age.
• Corticosteroid treatment led to significantly elevated CSF apoD levels.

Conclusions:

• This study provides the first evidence of increased intrathecal apoD production in MS.
• Elevated CSF apoD in CIDP/GBS suggests blood-nerve barrier compromise.
• ApoD levels and indices may serve as biomarkers for disease activity and progression in MS and other inflammatory neuropathies.